Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies
Pooled result · Kidney failure eventsResult — go to the resultHazard ratio 0.54 95% CI 0.47–0.63Authors' conclusion
The reno-protective benefits of SGLT2 inhibitors apply to a broad population of adults with T2D treated in routine clinical practice, including those at lower risk of kidney events with normal eGFR and without albuminuria. These findings support the early use of SGLT2 inhibitors in T2D for preservation of kidney health.
Study context
- Population
- Adults with T2D in real-world observational studies, 15 countries; searched to July 2022
- Participants
- 1,494,373 adults34 studies
- Comparison
- SGLT2i vs other glucose-lowering drugs
- Outcome
- Kidney failure events
Methodological detailsrandom-effects meta-analysis, ROBINS-I risk of bias assessment
- Random-effects meta-analysis
- ROBINS-I risk of bias assessment
Pooled result
As reported in the abstract
Hazard ratio
0.54
95% CI 0.47–0.63
SGLT2ivs Other glucose-lowering drugs
HR 0.54 (95% CI 0.47–0.63)
- Lower risk of kidney failure events with SGLT2i
- 46%
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Kidney failure, SGLT2ivs DPP-4i | 0.50 (0.38–0.67) | |
| Kidney failure, SGLT2ivs combination of other glucose-lowering drug classes | 0.51 (0.44–0.59) | |
| Kidney failure, SGLT2ivs GLP-1 RA | 0.93 (0.80–1.09) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies. Diabetes Obes Metab. Published 18 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →